Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
http://www.apogenix.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
0.7 seconds
16x16
Apogenix GmbH
Hartmut Voss
Im Neuen●●●●●●●●Feld 581
Hei●●●erg , 69120
DE
View this contact
Apogenix GmbH
Hartmut Voss
Im Neuen●●●●●●●●Feld 581
Hei●●●erg , 69120
DE
View this contact
1&1 Internet AG
Hostmaster EINSUNDEINS
Brau●●●●. 48
Kar●●●uhe , 76135
DE
View this contact
BUY YOUR DOMAIN
25
YEARS
6
MONTHS
20
DAYS
1 & 1 INTERNET AG
WHOIS : whois.schlund.info
REFERRED : http://1and1.com
PAGES IN
THIS WEBSITE
10
SSL
EXTERNAL LINKS
8
SITE IP
217.160.230.151
LOAD TIME
0.672 sec
SCORE
6.2
Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer and other malignant diseases | apogenix.com Reviews
https://apogenix.com
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
apogenix.com
Clinical Trials in MDS ǀ Apogenix
http://apogenix.com/en/clinical-trials/myelodysplastic-syndromes
Apogenix in the News. Phase I Trial with APG101 in MDS. About APG101 in MDS. Has been evaluated in a single arm phase I clinical trial for the treatment of myelodysplastic syndromes (MDS). The open-label study was conducted in two clinical centers in Germany (Heidelberg and Mannheim) and included twenty patients with low to intermediate-1 risk MDS who were transfusion dependent. Patients had to be refractory to erythropoietin-stimulating agents (ESA). The phase I trial has been completed, final data will...
Clinical Trials in Glioblastoma ǀ Apogenix
http://apogenix.com/en/clinical-trials/glioblastoma
Apogenix in the News. Phase II Trial with APG101 in Recurrent Glioblastoma. A total of 84 patients at 25 clinical sites in Germany, Austria, and Russia participated in this randomized controlled phase II efficacy trial in recurrent glioblastoma. The trial compared the efficacy and safety of a combination therapy of APG101. And radiotherapy versus radiotherapy alone. The treatment period has been completed and patients can no longer be included in this clinical trial. At the end of the follow-up perio...
Apogenix at Events ǀ Apogenix
http://apogenix.com/en/news-events/apogenix-at-events
Apogenix in the News. September 21 - 22, 2016. Participant: Thomas Hoeger, Ph.D., CEO. Panel - September 21, 3:20 pm: "Assessing how biomarkers can be used for predicting clinical benefit and adverse. Events in cancer immunotherapy". Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference:. Translating Science into Survival. September, 25 - 28, 2016. New York, USA. Participant: Christian Merz, PhD., Laboratory Head of Cellular Analytics. European Business Development Conference.
Careers ǀ Apogenix
http://apogenix.com/en/about-apogenix/career
Apogenix in the News. Apogenix maintains excellent relationships with renowned academic institutions conducting research in the fields of cancer and malignant diseases, and is part of an extensive international scientific and medical network. The company has established a leading position in the modulation of CD95L and TRAIL-mediated signaling pathways through newly engineered proteins. Phone : 49 (0)6221 586080.
Press Releases ǀ Apogenix
http://apogenix.com/en/news-events/press-release
Apogenix in the News. July 19, 2016. Apogenix granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes. June 15, 2016. Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101. May 4, 2016. Apogenix to Present at Two Upcoming International Conferences. March 24, 2016. Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes (MDS) published in. February 16, 2016. January 14, 2016. January 7, 2016. December 15, 2015.
TOTAL PAGES IN THIS WEBSITE
10
Clients - Bioscience Valuation
http://www.bioscience-valuation.com/clients.php
Through its 'Corporate Partnership Program', Bioscience Valuation has provided exceptional support in the tranformation of our business model. BSV's evidence-based assessments proved invaluable for our strategic decision making as well as for preparing our corporate transactions. ”. Peter Llewellyn-Davies, CFO/CBO. R&D Risk Analysis &. Corporate Finance / M&A. Healthcare / Life Science. Cell Technologies, s.l. Aesculap AG and Co. KG. AiCuris GmbH and Co. KG. Alternative Gene Expression S.L.
Agonist Immunotherapy Targets
http://www.pegsummit.com/Immunotherapy-Targets
Immunogenicity and Bioassays Stream. Attendee Demographics Event Features. Day 1 Day 2. THURSDAY, MAY 4. Case Studies with Agonist Antibodies. Luncheon in the Exhibit Hall with Poster Viewing. Peter Ellmark, Ph.D., Principal Scientist, Research and Development, Alligator Bioscience. KEYNOTE PRESENTATION: Engineering of an ICOS Agonist Antibody for Cancer Therapy. Axel Hoos, M.D., Ph.D., Senior Vice President, Therapeutic Area Head for Oncology R&D, GlaxoSmithKline Pharmaceuticals, Inc. Alligator Bioscien...
Personal weblog of Stephen Donner, or so they tell me... | Page 3
https://stephendonner.wordpress.com/page/3
Personal weblog of Stephen Donner, or so they tell me…. Http:/ www.vgxp.com/. Http:/ www.virionyx.com/. Http:/ www.virionyx.com/. Players in hair loss. Http:/ www.intercytex.com/. Http:/ www.follicabio.com/. Http:/ www.androscience.com/. Vitae Pharmaceuticals: Another Obesity Player. Another apoptosis company: Apogenix. The world can always use more players in the burgeoning apoptosis cancer pipeline; good to see Apogenix GmbH. Hey, the more in this field the merrier! Blog at WordPress.com. Personal webl...
VBU | VBU-Mitglieder
http://v-b-u.org/Unsere+Mitglieder.html
A Krüss Optronic GmbH. Andreas Hettich GmbH and Co. KG. Apceth GmbH and Co. KG. ASPIRAS Project Consulting in Pharma and Biotech. Biaffin GmbH and Co. KG. Bilfinger Industrietechnik Salzburg GmbH. BIOLOG Life Science Institute. Bio-M Biotech Cluster Development GmbH. BioSpring Gesellschaft für Biotechnologie mbH. BlueSens gas sensor GmbH. Boehringer Ingelheim Pharma GmbH and Co. KG. Bundesverband der Pharmazeutischen Industrie e.V. CONARIS Research Institute AG. DANA Patent Law Firm. ESAU and HUEBER GmbH.
Companies & Organizations | BioRN - Biotech-Cluster Rhine-Neckar
http://biorn.org/biorn-cluster/companies-organizations
Companies & Organizations. Partners & Networks. History & Awards. Health Axis Europe (HAE). European Health Science Match. Companies & Organizations. About the BioRN Cluster. Companies & Organizations. Basically, all companies and organizations that are situated close to Heidelberg, Mannheim, Ludwigshafen and Darmstadt and deal with medical biotechnology are called partners of the BioRN cluster. Here you can get an overview about our clusterpartner:. Abbott GmbH and Co. KG. AbbVie GmbH and Co. KG. Hardly...
Members | BioRN - Biotech-Cluster Rhine-Neckar
http://biorn.org/biorn-network/members
Companies & Organizations. Partners & Networks. History & Awards. Health Axis Europe (HAE). European Health Science Match. Our members are just one click away:. AbbVie Deutschland GmbH and Co. KG. BD Becton Dickinson GmbH. BIOCRATES Life Sciences AG. Cellzome GmbH, a GSK company. EMBL – European Molecular Biology Laboratory. EMBLEM Technology Transfer GmbH. Ernst and Young GmbH. German Cancer Research Center. HRS Health Research Services GmbH. Industrie- und Handelskammer Rhein-Neckar.
TOTAL LINKS TO THIS WEBSITE
8
Site Under Construction
This site is under construction. Please visit again to check the status. To go back to the previous page.
Stadt-Apotheke Gengenbach
Mo - Fr: 08:00 - 19:00 Uhr. Sa: 08:00 - 13:00 Uhr. Tel: 0800 5893693 (kostenlos). Wir begrüßen Sie herzlich auf unserer Website und laden Sie ein,. Sich über die vielseitigen Leistungen zu informieren, die wir für Sie bereithalten. Kommen Sie in der Apotheke vorbei oder besuchen Sie uns auf Facebook! Ihr Team der Stadt-Apotheke Gengenbach. Medizinische Droge oft verschrieben. Seit einem Jahr wird in Deutschland Cannabis legal bei der Behandlung von Patienten eingesetzt. Sowohl in der . mehr. Ensp; |.
Apogenics, Inc. |
Experienced advisors, providing advice and confidence. To make management better decisions. Apogenics solves the big challenges facing healthcare organizations. Starts with measuring what matters. Apogenics, Inc. is a trusted advisor to the world’s leading pharmaceutical, biotechnology and health services companies. Compliance and Regulatory advice for. 340B, Fair Market Value, and compliant. Some text goes here. Undefined variable: speed in. Undefined variable: speed in. Undefined variable: speed in.
Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer and other malignant diseases
Apogenix in the News. Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline. Of drug candidates that target different TNFSF. Dependent signaling pathways, thereby restoring the anti-tumor immune response. Clinical Efficacy in Two Indications. Our lead immuno-oncology candidate asunercept (APG101). The Apogenix team has created the HERA technology platform. For the development of novel he. May 29, 2017.
:: APOGEN REMEDIES PVT. LTD. ::
APOGEN REMEDIES PVT. LTD. Apogen Remedies Pvt. Ltd. Apogen. Driven by Quality and Innovation". Apogen, a Quality driven pharmaceutical company with a strong matrix of capabilities is presently focusing on research, development, manufacturing and marketing of Ready to fill pre formulation intermediates of Immediate and Modified release pellets for a wide range of generic drug formulations in various Therapeutic segments. Quality products for Quality Life through Innovation!
APO Gensan Alumni Association (APO GAAM)
APO Gensan Alumni Association (APO GAAM). See APO GAAM in Action. Here are the latest service projects accomplished by APO Gensan Alumni Association. APO GAAM Adopts Minanga Mangrove Area. APO GAAM gave its very own way of contributing to the health of our mother earth. We adopted Minanga Mangrove area because it is so close to a century coral that is spawning area to a lot of fish species inherent to Sarangani Bay. APO GAAM Celebrates 15th Anniversary. APO GAAM Celebrates 15th Anniversary.
int(rand() * rand()/(RAND_MAX+1.0)); | I was born in the wrong century for hats…
Int(rand() * rand()/(RAND MAX 1.0) ;. I was born in the wrong century for hats…. The Portrait and Story of Mademoiselle Irène Cahen d’Anvers. September 5, 2012. This is awfully boring, I just want to PLAY.” Even as a teenager and young adult, it was the first thing I would look for upon entering my grandparents’ house. After the death of Emil Georg Bührle in 1956, the portrait was eventually given to the Foundation E.G. Bührle in Zurich where it is now on display. I have not been to see it in...Be sure t...
apogentdiscoveries.com -
In der DNA sind alle Informationen für Bau und Funktion eines Lebewesens gespeichert. Kein Wunder, dass diese Substanz eine ungebrochene Faszination auf den Menschen ausübt und das Arbeiten mit DNA sicher zu den ersten Highlights im Biologiestudium gehört. Dabei sind die grundlegenden Methoden zum Umgang mit diesem Stoff so einfach, dass es sogar Experimente gibt, die in der Schule durchgeführt werden können. Hier möchte ich einige Methoden zum Arbeiten mit DNA vorstellen. Dies sind nur einige Beispiele ...
HOME
APOGEO s.r.l. Via Caduti di Nassiriya 170 - 70022 Altamura (BARI) -. Gennaio 14, 2018. Written by Pietro Pepe - Super User. La società Apogeo s.r.l. Si trova ad Altamura e dal 2001 svolge attività e offre servizi ambientali e territoriali con particolare riferimento alla geologia, geofisica e topografia di precisione. Opera su tutto il territorio nazionale e possiede l'attestazione SOA per le. Categorie OS20B Class. III bis. Indagini geognostiche) e OS20AClass. I. VISION: la società Apogeo. PROSPEZIONI S...
